Related Experiment Video

Updated: May 31, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive

Mariacarmela Santarpia1, Giuseppe Altavilla, Maria F Salazar

  • 1Human Pathology Department, Medical Oncology Unit, University of Messina, Italy.

Expert Review of Respiratory Medicine
|June 28, 2011
PubMed

Insights

Molecular-guided treatment for lung cancer, particularly using tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib, is improving patient outcomes. Identifying specific epidermal growth factor receptor (EGFR) mutations helps select patients most likely to benefit from these targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Lung cancer management is shifting towards personalized, molecular-guided treatments.
  • Tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib target specific genetic mutations in cancer cells.
  • Epidermal growth factor receptor (EGFR) mutations are key targets for TKI therapy in non-small-cell lung cancer.

Purpose of the Study:

  • To review the role of TKIs in lung cancer treatment.
  • To highlight the significance of EGFR mutations in predicting TKI response.
  • To discuss the identification of novel molecular alterations influencing TKI sensitivity and resistance.

Main Methods:

  • Review of clinical trials and scientific literature on TKIs for lung cancer.
  • Analysis of data on erlotinib and gefitinib efficacy in relation to EGFR mutations.
  • Exploration of emerging molecular targets and resistance mechanisms.

Main Results:

  • Erlotinib showed a survival advantage in unselected advanced non-small-cell lung cancer patients.
  • Gefitinib demonstrated higher response rates in specific patient subgroups with EGFR mutations.
  • Discovery of EGFR mutations elucidated the mechanism of TKI sensitivity.
  • Other molecular alterations affecting TKI efficacy have been identified.

Conclusions:

  • EGFR mutation status is a critical predictor of response to erlotinib and gefitinib.
  • Molecular profiling enables the selection of lung cancer patients most likely to benefit from TKIs.
  • Continued research into molecular alterations will further refine targeted lung cancer therapy.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...